Edwards Lifesciences reported strong first-quarter 2026 results, with sales rising 16.7% to $1.65 billion and adjusted earnings per share reaching $0.78. Growth was driven by continued demand for its transcatheter aortic valve replacement (TAVR) products, with TAVR sales increasing 14.4% to $1.20 billion.

The company also reported expanding momentum in its transcatheter mitral and tricuspid therapies segment, while completing a $500 million share repurchase program.

Edwards Lifesciences raised its full-year 2026 outlook, now expecting constant currency sales growth of 9% to 11% and higher adjusted EPS, reflecting confidence in continued demand and innovation in structural heart treatments.

Source: Business Wire